N'FORCE: Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Oct 6, 2026 - P2 | N=131 | Recruiting | Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Not yet recruiting ➔ Recruiting
Enrollment open • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck
|